Citations

Clear

26 citation(s) found for "Haley, William".

Effect of Intensive and Standard Clinic‐Based Hypertension Management on the Concordance Between Clinic and Ambulatory Blood Pressure and Blood Pressure Variability in SPRINT
Ghazi, Lama , Bates, Jeffrey T. , Chang, Tara I. , Haley, William E. , Johnson, Karen, Kostis, William J. , Simmons, Debra L., Taylor, Addison A. , Whelton, Paul K. , Wright, Jackson T. , Bhatt, Udayan, Drawz, Paul E. , Johnson, Karen , Drawz, Paul , Pajewski, Nicholas M. , Rifkin, Dena E. , Cushman, William C. , Glasser, Stephen P. , Papademetriou, Vasilios , Rahman, Mahboob , Ghazi, Lama

Mayo Clinic

Journal of the American Heart Association | July 16, 2019 | Volume: 8 | Issue: 14 | Pages: No page available

10.1161/jaha.118.011706 | PMID 31307270 Get It

Background Blood pressure ( BP ) varies over time within individual patients and across different BP measurement techniques. The effect of different BP targets on concordance between BP measurements is unknown. The goals of this analysis are to evaluate concordance between (1) clinic and ambulatory BP , (2) clinic visit‐to‐visit variability and ambulatory BP variability, and (3) first and second ambulatory BP and to evaluate whether different clinic targets affect these relationships. Methods and Results The SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory BP monitoring ancillary study obtained ambulatory BP readings in 897 participants at the 27‐month follow‐up visit and obtained a second reading in 203 participants 293±84 days afterward. There was considerable lack of agreement between clinic and daytime ambulatory systolic BP with wide limits of agreement in Bland‐Altman plots of −21 to 34 mm Hg in the intensive‐treatment group and −26 to 32 mm Hg in the standard‐treatment group. Overall, there was poor agreement between clinic visit‐to‐visit variability and ambulatory BP variability with correlation coefficients for systolic and diastolic BP all <0.16. We observed a high correlation between first and second ambulatory BP ; however, the limits of agreement were wide in both the intensive group (−27 to 21 mm Hg) and the standard group (−23 to 20 mm Hg). Conclusions We found low concordance in BP and BP variability between clinic and ambulatory BP and second ambulatory BP . Results did not differ by treatment arm. These results reinforce the need for multiple BP measurements before clinical decision making.
Symptomatic and Radiographic Manifestations of Kidney Stone Recurrence and Their Prediction by Risk Factors: A Prospective Cohort Study
D’Costa, Matthew R. , Haley, William E. , Mara, Kristin C. , Vrtiska, Terri J., Pais, Vernon M., Jacobsen, Steven J. , Rule, Andrew D. , Rule, Andrew D , Haley, William E , D'Costa, Matthew , Mara, Kristin C , Enders, Felicity , McCollough, Cynthia H. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | June 7, 2019 | Volume: 30 | Issue: 7 | Pages: 1251-1260

10.1681/asn.2018121241 | PMID 31175141 Get It

Significance Statement Kidney stone recurrence can manifest with symptoms from stone passage or with asymptomatic changes in kidney stone burden revealed by radiography. In a multicenter, prospective cohort study, the authors demonstrate that substantially more asymptomatic and self-managed symptomatic kidney stone recurrence occur in stone formers than has been appreciated, as many studies consider only symptomatic recurrence that results in clinical care. Among first-time symptomatic stone formers, 54% had an asymptomatic kidney stone; half of those with such a stone passed it within 5 years (but only half who did so experienced symptoms). The findings also show that when a more comprehensive definition of recurrence that includes all symptomatic and radiological manifestations is used, risk factors better predict kidney stone recurrence, thus supporting a comprehensive assessment of recurrence in clinical trials. Background Meaningful interpretation of changes in radiographic kidney stone burden requires understanding how radiographic recurrence relates to symptomatic recurrence and how established risk factors predict these different manifestations of recurrence. Methods We recruited first-time symptomatic stone formers from the general community in Minnesota and Florida. Baseline and 5-year follow-up study visits included computed tomography scans, surveys, and medical record review. We noted symptomatic recurrence detected by clinical care (through chart review) or self-report, and radiographic recurrence of any new stone, stone growth, or stone passage (comparing baseline and follow-up scans). To assess the prediction of different manifestations of recurrence, we used the Recurrence of Kidney Stone (ROKS) score, which sums multiple baseline risk factors. Results Among 175 stone formers, 19% had symptomatic recurrence detected by clinical care and 25% detected by self-report; radiographic recurrence manifested as a new stone in 35%, stone growth in 24%, and stone passage in 27%. Among those with a baseline asymptomatic stone (54%), at 5 years, 51% had radiographic evidence of stone passage (accompanied by symptoms in only 52%). Imaging evidence of a new stone or stone passage more strongly associated with symptomatic recurrence detected by clinical care than by self-report. The ROKS score weakly predicted one manifestation—symptomatic recurrence resulting in clinical care ( c -statistic, 0.63; 95% confidence interval, 0.52 to 0.73)—but strongly predicted any manifestation of symptomatic or radiographic recurrence (5-year rate, 67%; c -statistic, 0.79; 95% confidence interval, 0.72 to 0.86). Conclusions Recurrence after the first stone episode is both more common and more predictable when all manifestations of recurrence (symptomatic and radiographic) are considered.
Abstract P171: Effect of Intensive and Standard Clinic-Based Hypertension Management on the Concordance Between Clinic and Ambulatory Blood Pressure and Blood Pressure Variability: Systolic Blood Pressure Intervention Trial (SPRINT)
Bates, Jeffrey T. , Chang, Tara I. , Cushman, Wlliam C, Haley, William E. , Johnson, Karen, Pinion, Mary, Simmons, Debra L., Whelton, Paul K. , Wright, Jackson T. , Ghazi, Lama , Pajewski, Nicholas M. , Rifkin, Dena E. , Glasser, Stephen P. , Kostis, William J. , Papademetriou, Vasilios , Rahman, Mahboob , Taylor, Addison A. , Drawz, Paul E.

Mayo Clinic

Circulation | March 6, 2019 | Volume: 139 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.139.suppl_1.p171 Get It

Blood pressure (BP) varies over time within individual patients and across different BP measurement techniques. The effect of different BP targets on the concordance between BP measurements is unknown. The goal of this analysis was to evaluate concordance in: 1) clinic BP and ambulatory BP, 2) clinic visit-to-visit variability and ambulatory BP variability and 3) initial and repeat ambulatory BP. We also sought to evaluate whether treatment assignment of intensive vs standard BP target affected these relationships. The Systolic Blood Pressure Intervention Trial (SPRINT) ambulatory blood pressure monitoring ancillary study obtained ambulatory BP readings in 897 SPRINT participants at the 27 month follow up visit and 203 consecutive repeat ambulatory BP readings taken an average of 9.8 months later. There was poor agreement between clinic systolic BP and daytime ambulatory systolic BP (limits of agreement in Bland-Altman plots of -21 to 34 mm Hg in the intensive treatment group and -26 to 32 mm Hg in the standard treatment group). There was poor agreement between clinic visit-to-visit variability (coefficient of variation) and ambulatory BP variability (coefficient of variation of a 24 hr ambulatory BP) with correlation coefficients for systolic BP <0.16. While there was a high correlation between ambulatory BP at 27 months and repeat ambulatory BP (r ~0.56), there was significant variability between repeat ambulatory BP assessments (limits of agreement of -27 to 21 mm Hg in the intensive group and -23 to 20 mm Hg in the standard group). In conclusion, irrespective of treatment target, we found low concordance in BP and BP variability between clinic BP and ambulatory BP, and additionally between repeat ambulatory BP assessments. These results reinforce the need for multiple guideline adherent BP measurements prior to clinical decision making.
Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)
Shapiro, Brian P. , Ambrosius, Walter T. , Blackshear, Joseph L., Whelton, Paul K. , Oparil, Suzanne , Dwyer, Jamie P. , Kostis, William J. , Lioudis, Michael , Pisoni, Roberto, Rosendorff, Clive , Haley, William E. , Dwyer, Jamie P , Cushman, William C. , Beddhu, Srinivasan , Gren, Lisa H.

Mayo Clinic

Hypertension | April 30, 2018 | Volume: 71 | Issue: 6 | Pages: 1064-1074

10.1161/hypertensionaha.117.10646 | PMID 29712745 Get It

Intensive systolic blood pressure (SBP) control improved outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Our objective was to expand on reported findings by analysis of baseline characteristics, primary outcomes, adverse events, follow-up blood pressure, and medication use differences by baseline SBP (tertile 1 [T1], <132; tertile 2 [T2], 132–145; and tertile 3 [T3], >145 mm Hg). Participants with higher baseline SBP tertile were more often women and older, had higher cardiovascular risk, and lower utilization of antihypertensive medications, statins, and aspirin. Achieved SBP in both treatment arms was slightly higher in T2 and T3 compared with T1 and fewer in the T3 groups achieved SBP targets compared with T1 and T2 groups. The primary composite outcome with intensive versus standard SBP treatment was reduced by 30% in T1, 23% in T2, and 17% in T3 with no evidence of an interaction ( P =0.77). Event rates were lower in the intensive arm, and there was no evidence that this benefit differed by SBP tertile. There was no difference in the hazard for serious adverse events in any of the 3 tertiles. Medication utilization differed across the SBP tertiles at baseline with a lesser percentage of diuretics and angiotensin-converting enzyme inhibitors/angiotensin receptor blocker drugs in the higher tertiles—a finding that reversed during the trial. The beneficial effects of intensive SBP lowering were not modified by the level of baseline SBP. Within the parameters of this population, these findings add support for clinicians to treat blood pressure to goal irrespective of baseline SBP.
Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort
Dungan, Kathleen , Craven, Timothy E. , Soe, Kyaw , Wright, Jackson T. , Basile, Jan , Haley, William E. , Kressin, Nancy R. , Rani, Uzma , Tamariz, Leonardo , Whittle, Jeff , Wiggers, Alan , Osei, Kwame

Mayo Clinic

Diabetes, Obesity and Metabolism | October 12, 2017 | Volume: 20 | Issue: 3 | Pages: 629-637

10.1111/dom.13127 | PMID 29024310 Get It

Aims To determine whether baseline metabolic syndrome (MetS) modifies the effect of intensive blood pressure control on cardiovascular (CV) outcomes, and whether the effects varied by race/ethnicity. Methods We performed post hoc analyses among non‐Hispanic black, non‐hispanic white and Hispanic participants, with and without MetS, in the Systolic Blood Pressure Intervention Trial (SPRINT), who were randomized to a systolic blood pressure (SBP) target of <120 mm Hg (intensive group, N = 4544) or an SBP target of <140 mm Hg (standard group, N = 4553). The median follow‐up was 3.26 years. The primary outcome was the composite of the first occurrence of myocardial infarction, stroke, heart failure, non‐myocardial infarction acute coronary syndrome or CV death. Results Overall, 3521/9097 participants (38.7%) met the criteria for MetS at baseline. Baseline characteristics were similar in the two SBP target groups within each MetS subgroup, except body mass index was slightly higher in the standard arm of the MetS subgroup (33.3 ± 5.6 vs 33.0 ± 5.3 kg/m 2 ; P < .01), but were similar across treatment arms in the non‐MetS subgroup. The hazard ratio for the primary outcome was similarly reduced in participants with or without baseline MetS: 0.75 (95% confidence interval [CI] 0.57, 0.96) and 0.71 (95% CI 0.57, 0.87), respectively (adjusted P value for treatment by subgroup interaction = .98). Similarly, there was no evidence of treatment × MetS subgroup interaction for all‐cause mortality (adjusted interaction P value = .98). The findings were also similar across race/ethnic subgroups. Conclusions In this analysis the CV benefit of intensive SBP control did not differ among participants by baseline MetS status, regardless of race/ethnicity.
Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control
Chertow, Glenn M. , Cheung, Alfred K. , Greene, Tom , Wei, Guo , Campbell, Ruth , Conroy, Margaret, Haley, William E. , Horwitz, Edward , Kitzman, Dalane W. , Lash, James P. , Pisoni, Roberto, Riessen, Erik, Rosendorff, Clive , Watnick, Suzanne , Whittle, Jeff , Whelton, Paul K. , Haley, William, Greene, Tom , Beddhu, Srinivasan , Cushman, William C. , Rahman, Mahboob , Freedman, Barry I. , Papademetriou, Vasilios

Mayo Clinic

Circulation | October 11, 2017 | Volume: 137 | Issue: 2 | Pages: 134-143

10.1161/circulationaha.117.030848 | PMID 29021322 Get It

Background: In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear. Methods: SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized controlled trial that compared the effects of intensive (target <120 mm Hg) and standard (target <140 mm Hg) SBP control in 9361 older adults with high blood pressure at increased risk of cardiovascular disease. The primary outcome was a composite of cardiovascular disease events. All-cause death and incident chronic kidney disease were secondary outcomes. This post hoc analysis examined whether the effects of the SBP intervention differed by baseline DBP. Results: Mean baseline SBP and DBP were 139.7±15.6 and 78.1±11.9 mm Hg, respectively. Regardless of the randomized treatment, baseline DBP had a U-shaped association with the hazard of the primary cardiovascular disease outcome. However, the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline DBP level ( P for interaction=0.83). The primary outcome hazard ratio for intensive versus standard treatment was 0.78 (95% confidence interval, 0.57–1.07) in the lowest DBP quintile (mean baseline DBP, 61±5 mm Hg) and 0.74 (95% confidence interval, 0.61–0.90) in the upper 4 DBP quintiles (mean baseline DBP, 82±9 mm Hg), with an interaction P value of 0.78. Results were similar for all-cause death and kidney events. Conclusions: Low baseline DBP was associated with increased risk of cardiovascular disease events, but there was no evidence that the benefit of the intensive SBP lowering differed by baseline DBP. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01206062.
Effects of Intensive BP Control in CKD
CHEUNG, ALFRED K., Rahman, Mahboob, Reboussin, David M. , Craven, Timothy E., Greene, Tom, Pl, Kimmel, Hawfield, Amret , Johnson, Karen , Lewis, Cora E., Oparil, S, Rocco, Michael V., Sink, Kaycee M. , Pk, Whelton, Wright, Jackson T., Jn, Basile, Bhatt, Udayan, Chertow, Glenn M., Chonchol, M, Freedman, Barry I., Haley, William, Ix, J H, Katz, Lois A., Killeen, Anthony A. , Ricardo, Ana C., Servilla, Karen, Wall, Barry, Wolfgram, Dawn, Yee, Jerry , Chertow, Glenn M. , Greene, Tom , Rocco, Michael V. , Rahman, Mahboob , Craven, Tim, Cushman, William C. , Lewis, Cora E. , Beddhu, Srinivasan , Bhatt, Udayan, Chang, Tara I. , Chonchol, Michel , Freedman, Barry I. , Haley, William E. , Ix, Joachim H. , Katz, Lois Anne , Papademetriou, Vasilios , Servilla, Karen S. , Wolfgram, Dawn F. , Greene, Tom , Rocco, Michael V

Mayo Clinic

Journal of the American Society of Nephrology | June 22, 2017 | Volume: 28 | Issue: 9 | Pages: 2812-2823

10.1681/asn.2017020148 | PMID 28642330 Get It

The appropriate target for BP in patients with CKD and hypertension remains uncertain. We report prespecified subgroup analyses of outcomes in participants with baseline CKD in the Systolic Blood Pressure Intervention Trial. We randomly assigned participants to a systolic BP target of <120 mm Hg (intensive group; n =1330) or <140 mm Hg (standard group; n =1316). After a median follow-up of 3.3 years, the primary composite cardiovascular outcome occurred in 112 intensive group and 131 standard group CKD participants (hazard ratio [HR], 0.81; 95% confidence interval [95% CI], 0.63 to 1.05). The intensive group also had a lower rate of all-cause death (HR, 0.72; 95% CI, 0.53 to 0.99). Treatment effects did not differ between participants with and without CKD ( P values for interactions ≥0.30). The prespecified main kidney outcome, defined as the composite of ≥50% decrease in eGFR from baseline or ESRD, occurred in 15 intensive group and 16 standard group participants (HR, 0.90; 95% CI, 0.44 to 1.83). After the initial 6 months, the intensive group had a slightly higher rate of change in eGFR (−0.47 versus −0.32 ml/min per 1.73 m 2 per year; P <0.03). The overall rate of serious adverse events did not differ between treatment groups, although some specific adverse events occurred more often in the intensive group. Thus, among patients with CKD and hypertension without diabetes, targeting an SBP<120 mm Hg compared with <140 mm Hg reduced rates of major cardiovascular events and all-cause death without evidence of effect modifications by CKD or deleterious effect on the main kidney outcome.
The Capabilities and Limitations of Clinical Magnetic Resonance Imaging for Detecting Kidney Stones: A Retrospective Study
Ibrahim, El-Sayed H. , Cernigliaro, Joseph G. , Bridges, Mellena D., Pooley, Robert A. , Haley, William E. , Haley, William E

Mayo Clinic

International Journal of Biomedical Imaging | November 17, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-6

10.1155/2016/4935656 | PMID 27980535 Get It

The purpose of this work was to investigate the performance of currently available magnetic resonance imaging (MRI) for detecting kidney stones, compared to computed tomography (CT) results, and to determine the characteristics of successfully detected stones. Patients who had undergone both abdominal/pelvic CT and MRI exams within 30 days were studied. The images were reviewed by two expert radiologists blinded to the patients’ respective radiological diagnoses. The study consisted of four steps: (1) reviewing the MRI images and determining whether any kidney stone(s) are identified; (2) reviewing the corresponding CT images and confirming whether kidney stones are identified; (3) reviewing the MRI images a second time, armed with the information from the corresponding CT, noting whether any kidney stones are positively identified that were previously missed; (4) for all stones MRI-confirmed on previous steps, the radiologist experts being asked to answer whether in retrospect, with knowledge of size and location on corresponding CT, these stones would be affirmed as confidently identified on MRI or not. In this best-case scenario involving knowledge of stones and their locations on concurrent CT, radiologist experts detected 19% of kidney stones on MRI, with stone size being a major factor for stone identification.
The Clinical Impact of Accurate Cystine Calculi Characterization Using Dual-Energy Computed Tomography
Haley, William E. , Ibrahim, El-Sayed H. , Qu, Mingliang , Cernigliaro, Joseph G. , Goldfarb, David S. , McCollough, Cynthia H. , Goldfarb, David S

Mayo Clinic

Case Reports in Radiology | November 25, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-5

10.1155/2015/801021 | PMID 26688770 Get It

Dual-energy computed tomography (DECT) has recently been suggested as the imaging modality of choice for kidney stones due to its ability to provide information on stone composition. Standard postprocessing of the dual-energy images accurately identifies uric acid stones, but not other types. Cystine stones can be identified from DECT images when analyzed with advanced postprocessing. This case report describes clinical implications of accurate diagnosis of cystine stones using DECT.